These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21691817)

  • 21. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
    Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
    Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Markopoulos C; Tzoracoleftherakis E; Polychronis A; Venizelos B; Dafni U; Xepapadakis G; Papadiamantis J; Zobolas V; Misitzis J; Kalogerakos K; Sarantopoulou A; Siasos N; Koukouras D; Antonopoulou Z; Lazarou S; Gogas H
    Breast Cancer Res; 2010; 12(2):R24. PubMed ID: 20398352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
    Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
    Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
    J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
    Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
    Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
    Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
    Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
    J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
    Lustberg MB; Orchard TS; Reinbolt R; Andridge R; Pan X; Belury M; Cole R; Logan A; Layman R; Ramaswamy B; Wesolowski R; Berger M; Patterson E; Loprinzi C; Shapiro CL; Yee L
    Breast Cancer Res Treat; 2018 Feb; 167(3):709-718. PubMed ID: 29101597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.